10-Q: Cardinal Health Q1 FY26: Strong Revenue & Earnings Growth

Cardinal Health reports a robust start to fiscal year 2026 with significant revenue and operating earnings growth, driven by strategic acquisitions and strong pharmaceutical sales.

Summary

• Revenue for the three months ended September 30, 2025, increased 22% to $64.0 billion from the prior-year quarter.
• GAAP operating earnings increased 18% to $668 million, while non-GAAP operating earnings rose 37% to $857 million.
• GAAP diluted EPS increased 11% to $1.88, and non-GAAP diluted EPS increased 36% to $2.55.
• The Pharmaceutical and Specialty Solutions (Pharma) segment revenue grew 23% to $59.2 billion, and segment profit increased 26% to $667 million.
• The Global Medical Products and Distribution (GMPD) segment revenue increased 2% to $3.2 billion, with segment profit rising to $46 million from $8 million in the prior-year quarter.
• Other segment revenue increased 38% to $1.6 billion, and segment profit grew 60% to $166 million.
• Cardinal Health announced a definitive agreement to acquire Solaris Health, a urology MSO, for approximately $1.9 billion in cash, plus an estimated $500 million in common units to be issued.
• The company issued $1.0 billion in new debt (4.5% Notes due 2030 and 5.15% Notes due 2035) to fund a portion of the Solaris Health acquisition and for general purposes.
• Repaid $500 million of 3.75% Notes due 2025 at maturity.
• Deployed $375 million for share repurchases under an accelerated share repurchase (ASR) program.
• Made payments totaling $403 million related to opioid litigation during the quarter.
• Cash and equivalents increased to $4.6 billion at September 30, 2025, from $3.9 billion at June 30, 2025.
• Total long-term obligations, including current portion and other short-term borrowings, increased to $9.0 billion at September 30, 2025, from $8.5 billion at June 30, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue and non-GAAP earnings growth, driven by successful acquisitions and robust pharmaceutical sales. Positive cash flow from operations and strategic debt financing for growth initiatives are notable. However, increased interest expense, ongoing opioid litigation payments, and potential regulatory impacts on drug pricing and tariffs present headwinds.

Positives

• Strong revenue growth of 22% to $64.0 billion, driven by branded and specialty pharmaceutical sales and MSO acquisitions.
• Significant increase in non-GAAP operating earnings (37% to $857 million) and non-GAAP diluted EPS (36% to $2.55), indicating strong underlying business performance.
• Robust segment profit growth across all segments, with GMPD segment profit increasing from $8 million to $46 million and Other segment profit growing 60% to $166 million.
• Increased demand for GLP-1 pharmaceuticals positively impacted Pharma segment and consolidated revenue.
• The Pharma segment generics program positively impacted year-over-year segment profit.
• Net cash provided by operating activities was $973 million, a substantial improvement from a net cash used in operating activities of $(1,647) million in the prior-year quarter.
• Cash and equivalents increased to $4.6 billion, providing strong liquidity.
• No amounts outstanding under the commercial paper program, revolving credit facility, or committed receivables sales facility at quarter-end.
• Compliance with the consolidated net leverage ratio covenant of no more than 3.75-to-1.
• Received $5 million in insurance recoveries related to opioid matters during the quarter.

Negatives

• Interest expense, net, increased significantly to $80 million from $32 million in the prior-year quarter, primarily due to additional debt financing for recent acquisitions.
• Acquisition-related cash and share-based compensation costs were $64 million for the quarter.
• Corporate expenses increased substantially to $(211) million from $(74) million in the prior-year quarter.
• Gross margin rate remained relatively flat due to an unfavorable product mix in the Pharma segment, as increased branded pharmaceutical sales have a dilutive impact on the overall gross margin rate.
• Future demand for GLP-1 medications is unpredictable, and the ability to meet demand may be impacted by supply constraints.
• The recently issued Executive Order on 'Delivering Most-Favored Nation Prescription Drug Pricing to American Patients' may impact sales or profitability of branded pharmaceutical products, including GLP-1 products, with uncertain extent of impact.
• The adoption of the 'One Big Beautiful Bill Act' (OBBBA) could reduce participation in Medicare and Medicaid programs, potentially adversely affecting demand for products and services.
• Recent U.S. tariffs have resulted in substantial additional costs to source products and materials, and may lead to supply disruptions or shortages.
• Opioid litigation payments totaled $403 million for the quarter, representing a significant cash outflow.
• Total long-term obligations increased to $9.0 billion from $8.5 billion, increasing the company's debt burden.
• Shareholders' deficit increased to $(2,731) million from $(2,634) million.

Risks

• Competitive pressures in the markets, including pricing pressures.
• Uncertainties relating to the pricing of and demand for generic pharmaceuticals.
• Uncertainties related to recently imposed or threatened tariffs on goods from various countries, and any retaliatory actions, which may result in additional costs, supply disruptions, or shortages.
• Unpredictable timing, frequency, and profitability of generic pharmaceutical launches or other components of the pharmaceutical generics program.
• Material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies/defaults under contracts with key customers.
• Costs or claims resulting from quality issues, errors, or defects in manufacturing, sourcing, compounding, repackaging, information systems, or pharmacy management services, including recalls and product liability claims.
• Any compromise of information systems or those of third-party service providers, including unauthorized access, use, or disclosure of company or customer information.
• Continuing risks associated with the resolution and defense of opioid lawsuits and investigations, including those by the U.S. Department of Justice.
• Risks associated with the national opioid settlement agreement, including compliance costs and potential penalties for non-compliance.
• Uncertainties related to Cardinal Health Brand products, including the ability to manage cost and infrastructure, retain margin, increase volume, and improve performance.
• Significantly increased costs for commodities and other materials used in the Global Medical Products and Distribution segment manufacturing.
• Risks arising from acquisitions, including possible liabilities relating to prior operations and uncertainties relating to the ability to achieve anticipated results.
• Disruption, damage, or lack of access to, or failure of, information systems, critical facilities, or distribution networks.
• Risks associated with the Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services.
• High sales concentration with certain key customers, including CVS Health Corporation.
• Actions of regulatory bodies and other governmental authorities that could delay, limit, or suspend product development, manufacturing, distribution, importation, or sales, or result in sanctions.
• Shortages in commodities, components, raw materials, or energy used by businesses, including supply disruptions of radioisotopes.
• The loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available.
• Difficulties or delays in the development, production, manufacturing, sourcing, and marketing of new or existing products and services.
• Manufacturing disruptions due to regulatory action, production quality deviations, safety issues, raw material shortages, or reliance on single manufacturing facilities.
• Risks associated with industry reliance on Ethylene Oxide (EtO) to sterilize certain medical products, including potential regulatory actions and personal injury lawsuits.
• The possibility of adverse changes in tax laws or challenges to tax positions, including potential increases in the corporate tax rate.
• Risks arising from possible violations of healthcare fraud and abuse laws, U.S. Foreign Corrupt Practices Act, and other anti-corruption laws.
• Risks arising from collecting, handling, and maintaining patient-identifiable health information and other sensitive personal and financial information.
• Risks arising from certain businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, subject to accreditation and quality standards.
• Pharmaceutical manufacturers' restriction of sales under the 340B drug pricing program to contract pharmacies, which may adversely impact customers.
• Changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply.
• Unfavorable changes to the terms or inability to meet contractual obligations of key customer or supplier relationships.
• Uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements and prescription drug pricing transparency.
• Reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services.
• Changes in manufacturers' pricing, selling, inventory, distribution, or supply policies or practices.
• Continuing consolidation in the healthcare industry, which could increase bargaining power for resulting enterprises and pressure on prices.
• Losses relating to product liability lawsuits and claims regarding products for which insurance may not be adequate, including Cordis IVC filter products.
• Risks associated with the importation of products or source materials, including country-of-origin determinations and the Uyghur Forced Labor Prevention Act.
• The possibility that business performance or internal control over financial reporting may be adversely impacted if the company is not successful at attracting, retaining, and developing talent.
• Significant charges to earnings if goodwill or intangible assets become impaired.
• Uncertainties relating to general political, business, industry, regulatory, and market conditions.

Future Outlook

Cardinal Health expects further growth in Cardinal Health brand medical products sales during the remainder of fiscal 2026 and beyond. The company acknowledges that future demand for GLP-1 medications is unpredictable and may be impacted by supply constraints. The Executive Order on 'Most-Favored Nation Prescription Drug Pricing' and the 'One Big Beautiful Bill Act' (OBBBA) could impact sales or profitability of branded pharmaceutical products and reduce participation in Medicare and Medicaid programs, respectively, though the extent of these impacts is uncertain. Tariffs are expected to continue resulting in additional costs and potential supply disruptions. The majority of remaining opioid litigation payments are anticipated through 2038. The Accelerated Share Repurchase program will conclude by October 31, 2025, and the 364-Day revolving credit facility and committed receivables sales facility program have been renewed through October 2026 and September 2028, respectively. No material impact is expected from OBBBA on the effective tax rate in future periods.

Management Comments

• "We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs."
• "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing."
• "We intend to vigorously defend ourselves in this matter [West Virginia opioid case]."
• "We intend to continue to vigorously defend ourselves in the remaining lawsuits [IVC filter product liability claims]."

Industry Context

The U.S. healthcare industry is undergoing significant transformations aimed at increasing access to care, improving patient outcomes, containing costs, and enhancing efficiencies. These changes include a general decline in Medicare and Medicaid reimbursement levels, efforts by healthcare insurance companies to limit payments, a shift towards value-based payments, and a move from traditional hospital settings to clinics, physician offices, and home care. The increased demand for GLP-1 pharmaceuticals highlights a dynamic and growing segment within the pharmaceutical market. The industry also faces heightened governmental scrutiny, with potential impacts from new legislation on prescription drug pricing, such as the 'Most-Favored Nation Prescription Drug Pricing' Executive Order and the 'One Big Beautiful Bill Act,' as well as ongoing challenges like the 340B drug pricing program restrictions. Continuing consolidation within the healthcare sector could further intensify competitive pressures and impact pricing for products and services.

Comparison to Industry Standards

• The company's strategic partnership in Red Oak Sourcing, LLC with CVS Health Corporation for generic pharmaceutical sourcing positions it with a major industry player, indicating a collaborative approach to supply chain efficiency common among large distributors.
• The acquisition of Solaris Health, described as the 'country's leading urology MSO,' demonstrates Cardinal Health's aggressive expansion into physician practice management, a growing trend among healthcare service providers seeking to integrate care coordination and capture value across the healthcare continuum.
• The significant increase in demand for GLP-1 pharmaceuticals reflects a broader industry trend of high-growth specialty drug categories, which many pharmaceutical distributors are leveraging, though the company notes the unpredictability of future demand and potential supply constraints.
• The discussion of potential impacts from the 'Most-Favored Nation Prescription Drug Pricing' Executive Order and the 'One Big Beautiful Bill Act' highlights industry-wide regulatory challenges that affect all major pharmaceutical distributors and healthcare providers, not just Cardinal Health.
• The ongoing opioid litigation and settlements are a pervasive issue across the pharmaceutical distribution industry, with Cardinal Health's accrued liabilities and payment schedule reflecting a common, albeit substantial, financial and operational burden shared by its peers.

Corporate Governance

Legal Proceedings

• Accrued $4.3 billion as of September 30, 2025, for opioid-related matters, with $403 million paid during the quarter.
• Expect to pay additional amounts up to $4.1 billion through 2038 under the National Opioid Settlement Agreement (NOSA).
• The United States Court of Appeals for the Fourth Circuit vacated a judgment in favor of the Distributors in a West Virginia opioid case and remanded for further proceedings.
• Approximately 195 lawsuits brought by private plaintiffs related to opioids were pending as of October 28, 2025, including about 51 purported class actions.
• Finalized agreements with classes of third-party payors and acute care hospitals for the company's portion of $213 million.
• Received $5 million in insurance recoveries related to opioid matters during the quarter.
• Received a Civil Investigative Demand (CID) from the Department of Justice in November 2023, focusing on potential Anti-Kickback Statute and False Claims Act violations related to a 2022 transaction.
• Accrued $40 million for losses and legal defense costs related to Cordis IVC filter product liability lawsuits as of September 30, 2025, including $37 million in a qualified settlement fund.
• The New York Appellate Division held the 2017 assessment under the Opioid Stewardship Act (OSA) unconstitutionally retroactive, leading to a settlement for a refund of the portion paid for calendar year 2017.

Related Party Transactions

• Cardinal Health established Red Oak Sourcing, LLC, a U.S.-based generic pharmaceutical sourcing venture with CVS Health Corporation, and is required to make quarterly payments to CVS Health for the term of the arrangement, which was extended through June 2029.
• The company has a high sales concentration with certain key customers, including CVS Health Corporation.

Stakeholder Impact

• Shareholders: Positive impact from strong earnings growth and share repurchases, but potential dilution from MSO common unit issuance and increased debt levels.
• Employees: Restructuring and employee severance costs indicate ongoing cost-savings measures and rationalization, potentially affecting some employees.
• Customers: Increased demand for GLP-1 pharmaceuticals and Cardinal Health brand medical products. Potential adverse impact from tariffs leading to price increases or supply disruptions, and from 340B program restrictions.
• Suppliers: Potential impact from tariffs and the company's efforts to seek alternative sources of supply.
• Creditors: Increased long-term debt, but the company remains in compliance with financial covenants and demonstrates strong operating cash flow.
• Physicians and Management of Acquired MSOs: Issuance of common units in the Specialty Alliance as part of acquisition consideration, aligning interests.

Next Steps

• Close the acquisition of Solaris Health, subject to the satisfaction of customary closing conditions, including receipt of required physician and regulatory approvals.
• Conclude the Accelerated Share Repurchase (ASR) program by October 31, 2025.
• Continue to assess the implications of the One Big Beautiful Bill Act (OBBBA) as further guidance becomes available.
• Vigorously defend against remaining opioid lawsuits and IVC filter product liability claims.
• Monitor compliance with the Injunctive Relief provisions of the National Opioid Settlement Agreement (NOSA) until 2027.
• Fund the third-party vendor clearinghouse for data aggregation and reporting until 2032.
• Evaluate the impact of ASU 2023-09 (Income Taxes) for the 2026 Form 10-K.
• Evaluate the impact of ASU 2024-03 (Expense Disaggregation Disclosures) for the fiscal 2028 Form 10-K.

Key Dates

Recommendation

Cardinal Health delivered a strong Q1 FY26 with significant revenue and non-GAAP earnings growth, driven by strategic acquisitions and robust pharmaceutical sales, particularly in branded and specialty products. The acquisition of Solaris Health further strengthens its MSO platforms. However, the company faces increasing interest expenses due to new debt, ongoing substantial opioid litigation payments, and significant regulatory uncertainties related to drug pricing and tariffs. While operational performance is strong, these external factors and the increase in long-term debt warrant a cautious 'hold' recommendation, as the positive operational momentum is balanced by these considerable risks and costs.

Keywords

Healthcare services, Pharmaceutical distribution, Medical products, MSO platforms, Acquisitions, GLP-1, Generics program, Opioid litigation, Supply chain, Q1 Fiscal 2026, Cardinal Health, CAH, 10-Q, Financial results, Earnings, Revenue, EPS, Debt financing, Share repurchase, Solaris Health